Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018
Introduction
Myocarditis (inflammation of the myocardium, or heart muscle) and pericarditis (inflammation of the pericardium, or tissue overlying the heart muscle) often occur together (termed myopericarditis), and can range in severity from mild and without symptoms, to severe [1]. Myopericarditis has many causes, including viral infections [1].
Although not establishing causality, myopericarditis has been reported after vaccinations. Myopericarditis is known to occur after administration of smallpox vaccine [2]. Amsel et al., described myocarditis in a male aged 3 months after receiving both combined diphtheria, tetanus, and pertussis (DTP) vaccine, and oral polio vaccine [3]. de Meester et al. described pericarditis after vaccination with influenza vaccine [4], Peyriere et al. described pericarditis after hepatitis B vaccine [5], and Mei et al. have described recurrent pericarditis after inactivated influenza (IIV) [6]. Except for smallpox vaccine, none of these reports described vaccines licensed for use in the United States.
Myopericarditis after live virus vaccines other than smallpox vaccine has been explored to some degree [7], [8]. Reports of myopericarditis after inactivated vaccines have been scant, mostly after IIV [4], [9], including a recently published case report attributing myocarditis to adjuvanted inactivated influenza vaccine (Fluad® , Sequirus) [9]. Further, several vaccines that are not IIV – including both live attenuated and inactivated vaccines – have been licensed for use in the United States over the past several years. To better characterize myopericarditis after vaccination, we reviewed and described reports of myopericarditis received by the Vaccine Adverse Event Reporting System (VAERS).
Section snippets
Data source
VAERS is a national spontaneous reporting system for monitoring AEs after vaccination [10]. Reports of AEs following vaccines licensed for use in the United States are accepted from healthcare providers, vaccine manufacturers, vaccine recipients and other persons and entities, including the military. Reported signs and symptoms are coded using Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) [11]. MedDRA PTs are not necessarily medically confirmed diagnoses, and a
Descriptive analysis
During the analytic period, VAERS received a total of 620,195 reports. Of these reports, 708 (0.1%) either met the published case definition for myopericarditis [14] or were diagnosed by a physician as myopericarditis (Table 1). Most reports described males (79%), and most reports were classified as serious (69%), with a reported time to symptom onset of 14 days or less (72%). Median reported age was 24 years (range: 0 to 90 years): among people ≤ 18 years of age, median age was 8 years (range:
Discussion
We performed a comprehensive review of post-licensure vaccine surveillance data on myopericarditis, using both a published case definition [14] and review of medical records to identify such reports. Smallpox vaccine remained the most commonly reported vaccine, while other reported vaccines were consistent with vaccine types recommended for the given age group of the patient and therefore might reflect relative frequencies of vaccine exposures per recommended schedules for vaccination [17], [18]
Note
This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC), or the US Food and Drug Administration (FDA). Mention of a product or company name does not constitute endorsement by the CDC or FDA.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References (33)
- et al.
Smallpox vaccination and myopericarditis: a clinical review
J Am Coll Cardiol
(2004) - et al.
Symptomatic pericarditis after influenza vaccination: report of two cases
Chest
(2000) - et al.
Acute pericarditis after vaccination against hepatitis B: a rare effect to be known
Rev Med Interne
(1997) - et al.
Myocarditis and pericarditis are rare following live viral vaccinations in adults
Vaccine
(2018) - et al.
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Vaccine
(2015) - et al.
Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis
Brain Behav Immun
(2009) - et al.
Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel
Vaccine
(2020) - et al.
Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6–23 months of age
Vaccine
(2009) - et al.
Acute myopericarditis after diphtheria, tetanus, and polio vaccination
Chest
(2001) - et al.
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015
Vaccine
(2018)
Management of myopericarditis
Expert Rev Cardiovasc Ther
Myocarditis after triple immunisation
Arch Dis Child
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
BMC Pharmacol Toxicol
Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study
J Intern Med
Acute Fulminant Myocarditis Following Influenza Vaccination Requiring Extracorporeal Membrane Oxygenation
Acute Crit Care
Cited by (103)
Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis
2024, The Lancet Global HealthBenefits v. risks of COVID-19 vaccination: an examination of vaccination policy impact on the occurrence of myocarditis and pericarditis
2023, The Lancet Regional Health - Western PacificMyocarditis Following COVID-19 Vaccination
2023, Heart Failure Clinics
- 1
Currently at Division of Health Economics, Policy and Management, University of Hong Kong, School of Public Health.